News

The collaboration between HTG and Bristol-Myers Squibb will utilize the next generation sequencing (NGS)-based HTG EdgeSeq system as a tool for use in support of Bristol-Myers Squibb’s translational

In its written response, the FDA advised Tetraphase that data from one additional positive phase 3 clinical trial will be required to support a New Drug Application (NDA)

Under the settlement and license agreement, Horizon has granted Teligent the non-exclusive right to market a generic diclofenac sodium topical 2% w/w solution in the United States under

The Phase 1 portion of the seviteronel study has completed and a once-daily dose was selected for advancement into Phase 2 development. William Moore, Ph.D., Innocrin’s Chief Executive

Orphan drug designation provides certain exclusivity benefits, tax credits for certain research, longer exclusivity and a waiver of the New Drug Application user fee. The designation is made

An independent data monitoring committee observed that patients taking the drug in the trial were at a possible increased risk for death and other severe adverse events as

About 60,000 people in the US are diagnosed with DTC per year, and radioactive iodine (RAI) is recommended for those with known/suspected metastases at diagnosis and at high

Additional new investors include Aju IB Investment, Cowen Private Investments, Franklin Templeton Investments and Rock Springs Capital. All existing investors participated in the financing: Eshelman Ventures, Hatteras Venture

The compound is an oral and selective small molecule modulator of splicing factor 3b subunit 1 (SF3B1), which is being developed by H3 Biomedicine as an anticancer therapeutic